Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.
Bagdanoff, J.T., Jain, R., Han, W., Zhu, S., Madiera, A.M., Lee, P.S., Ma, X., Poon, D.(2015) Bioorg Med Chem Lett 25: 3788-3792
- PubMed: 26259804 
- DOI: https://doi.org/10.1016/j.bmcl.2015.07.091
- Primary Citation of Related Structures:  
5BVD, 5BVE, 5BVF - PubMed Abstract: 
A series of structure based drug design hypotheses and focused screening efforts led to the identification of tetrahydropyrrolo-diazepenones with striking potency against ERK2 kinase. The role of fluorination in mitigating microsomal clearance was systematically explored. Ultimately, it was found that fluorination of a cyclopentanol substructure provided significant improvement in both potency and human metabolic stability.
Organizational Affiliation: 
Global Discovery Chemistry/Oncology and Exploratory Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Ave., Cambridge, MA 02139, USA. Electronic address: jeffrey.bagdanoff@novartis.com.